TISIDB

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane; Multi-pass membrane protein.
Domain	PF01569 PAP2 superfamily
Function	Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it is the key enzyme in homeostatic regulation of blood glucose levels.

> Gene Ontology [ TOP ]
Biological Process	GO:0000272 polysaccharide catabolic process GO:0005976 polysaccharide metabolic process GO:0005977 glycogen metabolic process GO:0005980 glycogen catabolic process GO:0005996 monosaccharide metabolic process GO:0006006 glucose metabolic process GO:0006073 cellular glucan metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006094 gluconeogenesis GO:0006112 energy reserve metabolic process GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0008202 steroid metabolic process GO:0008643 carbohydrate transport GO:0008645 hexose transport GO:0009251 glucan catabolic process GO:0009991 response to extracellular stimulus GO:0015712 hexose phosphate transport GO:0015748 organophosphate ester transport GO:0015749 monosaccharide transport GO:0015758 glucose transport GO:0015760 glucose-6-phosphate transport GO:0015980 energy derivation by oxidation of organic compounds GO:0016051 carbohydrate biosynthetic process GO:0016052 carbohydrate catabolic process GO:0016311 dephosphorylation GO:0019318 hexose metabolic process GO:0019319 hexose biosynthetic process GO:0031667 response to nutrient levels GO:0032094 response to food GO:0033500 carbohydrate homeostasis GO:0035264 multicellular organism growth GO:0042593 glucose homeostasis GO:0042632 cholesterol homeostasis GO:0044042 glucan metabolic process GO:0044247 cellular polysaccharide catabolic process GO:0044262 cellular carbohydrate metabolic process GO:0044264 cellular polysaccharide metabolic process GO:0044275 cellular carbohydrate catabolic process GO:0044283 small molecule biosynthetic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0046364 monosaccharide biosynthetic process GO:0046415 urate metabolic process GO:0046486 glycerolipid metabolic process GO:0046838 phosphorylated carbohydrate dephosphorylation GO:0051156 glucose 6-phosphate metabolic process GO:0055088 lipid homeostasis GO:0055092 sterol homeostasis GO:1901264 carbohydrate derivative transport
Molecular Function	GO:0004346 glucose-6-phosphatase activity GO:0016791 phosphatase activity GO:0019203 carbohydrate phosphatase activity GO:0042301 phosphate ion binding GO:0042578 phosphoric ester hydrolase activity GO:0043168 anion binding GO:0050308 sugar-phosphatase activity GO:0050309 sugar-terminal-phosphatase activity
Cellular Component	GO:0030176 integral component of endoplasmic reticulum membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04068 FoxO signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04152 AMPK signaling pathway hsa04910 Insulin signaling pathway hsa04920 Adipocytokine signaling pathway hsa04922 Glucagon signaling pathway hsa04973 Carbohydrate digestion and absorption hsa00010 Glycolysis / Gluconeogenesis hsa00052 Galactose metabolism hsa00500 Starch and sucrose metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-70153: Glucose transport R-HSA-189200: Hexose transport R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-425407: SLC-mediated transmembrane transport R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between G6PC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of G6PC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of G6PC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.687	0.242
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.203	0.158
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.922	0.233
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.703	0.57
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.185	0.366
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.916	0.338
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.247	0.517
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.269	0.882
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.152	0.898
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.223	0.42
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.689	0.0377

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of G6PC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	4.1	3.3	0.61
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of G6PC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of G6PC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by G6PC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of G6PC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of G6PC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between G6PC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	G6PC
Name	glucose-6-phosphatase, catalytic subunit
Aliases	GSD1a; glycogen storage disease type I, von Gierke disease; G6PT; glucose-6-phosphatase, catalytic (glycogen ......
Chromosomal Location	17q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting G6PC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse G6PC